Definitive Healthcare's Q4 2023 performance, with adjusted EPS at $0.07, sales of $65.93 million, and a 5% Y/Y growth in enterprise clients. Get insights into Q1 2024 guidance and fiscal year 2024 expectations, despite macroeconomic challenges. Analysts note resilience and positive developments, maintaining an Outperform rating.
What is abnormal uterine bleeding, its impact on women’s health, and current standards of care and treatments? Introducing Avana Health s drug-plus-device solution.
As channels look for new revenue opportunities, healthtech is the ‘next big thing’ – particularly with aging boomers and reaching underserved populations.
Presenter SpeechJared Haase Good afternoon, everyone. Thanks for joining us here for the Definitive Health care session. Just as a quick intro. My name is Jared Haase. I worked on the health care IT. | June 7, 2023